Skip to main content
. 2020 Apr 3;11:542. doi: 10.3389/fimmu.2020.00542

Figure 3.

Figure 3

IFNα9 enhances anti-tumor immunity against bystander WT B16 tumors. (A) RAGo/o mice were inoculated subcutaneously with 5 × 105 B16_GFP or B16_IFNα cells. Tumor growth was measured over time. Each point signifies mean ± SEM from two independent experiments (n = 10–12 per group). Tumor growth curves of B16_GFP vs. each B16_IFNα were compared using repeated-measure two-way ANOVA (mixed-model) followed by the Bonferroni post hoc test, ****p < 0.0001. (B) Proportions of RAGo/o mice that developed palpable tumors over time. (C) Tumor growth and (D) incidence of WT mice inoculated subcutaneously with 5 × 104 bystander WT B16_Cherry cells alone or 5 × 104 B16_Cherry cells mixed with 4.5 × 105 B16_IFNα9 cells. Data combined from two independent experiments (n = 10 per group). B16_Cherry vs. B16_Cherry + B16_IFNα9 tumor growth curves were compared using repeated-measure two-way ANOVA (mixed-model) followed by the Bonferroni post hoc test and tumor incidence was compared using the Log-Rank Mantel-Cox test, ****p < 0.0001.